Ascentage Pharma director reports option and RSU holdings

Ascentage Pharma Group International director Marina Bozilenko has filed an initial ownership report showing equity-based compensation holdings.

Accepted by SEC EDGAR 03/19/2026 - 11:43 AM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ascentage Pharma Group International director Marina Bozilenko has filed an initial ownership report showing equity-based compensation holdings. She holds stock options over 53,895 Ordinary Shares with an exercise price of $8.14 per share, expiring on November 26, 2035. These options vest in four equal installments on each of November 26, 2026, 2027, 2028 and 2029.

She also holds restricted stock units representing 63,895 Ordinary Shares. Each RSU converts into one Ordinary Share upon vesting, with the RSUs vesting in four equal installments on the same dates from 2026 through 2029 and having no expiration date. This filing records existing awards and does not show any buy or sell transactions.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Bozilenko Marina

Role Director

Type	Security	Shares	Price	Value
Holding	Options	--	--	--
Holding	Restricted stock units	--	--	--

Holdings: Options — 53,895 contracts (Direct); Restricted stock units — 63,895 contracts (Direct)

Footnotes (3)

F1. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
F2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
F3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Marina Bozilenko report in her Form 3 for AAPG?

She reported existing equity awards in Ascentage Pharma Group International, including stock options and restricted stock units. The filing is an initial ownership statement and does not disclose any new purchases or sales of the company’s shares.

How many Ascentage Pharma (AAPG) shares are covered by Marina Bozilenko’s options?

Her stock options are exercisable for 53,895 Ordinary Shares of Ascentage Pharma Group International. These options carry an exercise price of $8.14 per share and expire on November 26, 2035, with vesting spread across four annual installments.

What are the terms of Marina Bozilenko’s restricted stock units in AAPG?

She holds restricted stock units linked to 63,895 Ordinary Shares of Ascentage Pharma Group International. Each RSU converts into one share upon vesting, which occurs in four equal annual installments from November 26, 2026 through November 26, 2029.

Do the reported AAPG option awards for Marina Bozilenko have a vesting schedule?

Yes. The stock options vest in four equal increments on November 26 of 2026, 2027, 2028 and 2029. This staged vesting ties her equity compensation to continued service and long-term alignment with Ascentage Pharma’s performance.

Do Marina Bozilenko’s AAPG restricted stock units have an expiration date?

The restricted stock units do not have an expiration date. They represent contingent rights to receive Ordinary Shares of Ascentage Pharma Group International, vesting in four equal annual installments from November 26, 2026 through November 26, 2029.

Does Marina Bozilenko’s Form 3 for AAPG show any insider buying or selling?

No. The Form 3 records her existing holdings of options and restricted stock units in Ascentage Pharma Group International. It does not report any open-market purchases, sales, or other buy or sell transactions in the company’s shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bozilenko Marina

(Last)

(First)

(Middle)

700 KING FARM BLVD

STE 510

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options	⁽¹⁾	11/26/2035	Ordinary Shares	53,895	$8.14⁽²⁾	D
Restricted stock units	⁽³⁾	⁽³⁾	Ordinary Shares	63,895	$0	D

Explanation of Responses:

1. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.

Remarks:

	Marina Bozilenko	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR